April 23, 2012Other Transplantationadmin BioTime, Inc. announced today that Charles S. Irving, Ph.D., the CEO of BioTime’s subsidiary Cell Cure Neurosciences, Ltd. will provide an update on the development of OpRegen® at an investor meeting in New York City.
